These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25322754)

  • 1. Angiogenic gene therapy does not cause retinal pathology.
    Prokosch V; Stupp T; Spaniol K; Pham E; Nikol S
    J Gene Med; 2014; 16(9-10):309-16. PubMed ID: 25322754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.
    Nikol S; Baumgartner I; Van Belle E; Diehm C; Visoná A; Capogrossi MC; Ferreira-Maldent N; Gallino A; Wyatt MG; Wijesinghe LD; Fusari M; Stephan D; Emmerich J; Pompilio G; Vermassen F; Pham E; Grek V; Coleman M; Meyer F;
    Mol Ther; 2008 May; 16(5):972-8. PubMed ID: 18388929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia.
    Baumgartner I; Chronos N; Comerota A; Henry T; Pasquet JP; Finiels F; Caron A; Dedieu JF; Pilsudski R; Delaère P
    Mol Ther; 2009 May; 17(5):914-21. PubMed ID: 19240689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia.
    Maulik N
    Curr Opin Investig Drugs; 2009 Mar; 10(3):259-68. PubMed ID: 19333884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial.
    Comerota AJ; Throm RC; Miller KA; Henry T; Chronos N; Laird J; Sequeira R; Kent CK; Bacchetta M; Goldman C; Salenius JP; Schmieder FA; Pilsudski R
    J Vasc Surg; 2002 May; 35(5):930-6. PubMed ID: 12021709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease.
    Niebuhr A; Henry T; Goldman J; Baumgartner I; van Belle E; Gerss J; Hirsch AT; Nikol S
    Gene Ther; 2012 Mar; 19(3):264-70. PubMed ID: 21716303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.
    Scott IU; Jackson GR; Quillen DA; Larsen M; Klein R; Liao J; Holfort S; Munch IC; Gardner TW
    JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia.
    Nikol S; Baumgartner I; Van Belle E; Diehm C; Visoná A; Capogrossi MC; Ferreira-Maldent N; Gallino A; Graham Wyatt M; Dinesh Wijesinghe L; Fusari M; Stephan D; Emmerich J; Pompilio G; Vermassen F; Pham E; Grek V; Coleman M; Meyer F
    Mol Ther; 2008 May; 16(5):972-978. PubMed ID: 28178491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.
    Belch J; Hiatt WR; Baumgartner I; Driver IV; Nikol S; Norgren L; Van Belle E;
    Lancet; 2011 Jun; 377(9781):1929-37. PubMed ID: 21621834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia.
    Van Belle E; Nikol S; Norgren L; Baumgartner I; Driver V; Hiatt WR; Belch J
    Eur J Vasc Endovasc Surg; 2011 Sep; 42(3):365-73. PubMed ID: 21696982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
    Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
    Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into gene therapy for critical limb ischemia: the devil is in the details.
    Madonna R; Rokosh G
    Vascul Pharmacol; 2012 Aug; 57(1):10-4. PubMed ID: 22580542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
    Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
    Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy.
    Xu H; Zhang L; Gu L; Lu L; Gao G; Li W; Xu G; Wang J; Gao F; Xu JY; Yao J; Wang F; Zhang J; Xu GT
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1519-30. PubMed ID: 24508793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.
    Gu Y; Cui S; Wang Q; Liu C; Jin B; Guo W; Liu C; Chu T; Shu C; Zhang F; Han C; Liu Y
    Mol Ther; 2019 Dec; 27(12):2158-2165. PubMed ID: 31805256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic angiogenesis using gene transfer and stem cell therapy in peripheral artery disease].
    Nikol S
    Dtsch Med Wochenschr; 2011 Apr; 136(14):672-4. PubMed ID: 21448824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4.
    Matyas L; Schulte KL; Dormandy JA; Norgren L; Sowade O; Grötzbach G; Palmer-Kazen U; Rubanyi GM; Wahlberg E
    Hum Gene Ther; 2005 Oct; 16(10):1202-11. PubMed ID: 16218781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters.
    Caron A; Michelet S; Caron A; Sordello S; Ivanov MA; Delaère P; Branellec D; Schwartz B; Emmanuel F
    J Gene Med; 2004 Sep; 6(9):1033-45. PubMed ID: 15352076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.